Drug intelligence / Profile preview

VDN 0100

Development stage: Preclinical
Lead developer: Vedana Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

VDN 0100 is a preclinical-stage anti-PACAP monoclonal antibody being developed by Vedana Therapeutics for the prevention of migraine. It is designed to inhibit the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) pathway, which is a key mediator in migraine pathophysiology alongside CGRP. By neutralizing PACAP, VDN 0100 aims to provide a therapeutic option for patients who do not respond adequately to existing CGRP-targeted therapies. The company plans to initiate First-in-Human (FiH) clinical trials in 2027.

Other names: VDN 0100VDN0100VDN-0100

Targets

PACAP (Pituitary adenylate cyclase-activating polypeptide)

Beyond the preview

Go deeper on VDN 0100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDN 0100.

Explore the full profile